July 1, 2014

L'Oréal USA announced that it has reached an agreement with the Federal Trade Commission, ending an inquiry regarding certain advertising claims that were discontinued some time ago.

June 24, 2014

The Federal Trade Commission is stepping up probes of pay-for-delay settlements — pharmaceutical deals that delay the sale of generic drugs — according to a report published Monday by Bloomberg.

May 27, 2014

The 7th annual Retail Clinician Education Congress was held from May 12 to 15, and the program lineup was outstanding this year. From clinical sessions featuring healthcare experts in the industry, such as Alan Agins and Wendy Wright, to executive and leadership sessions featuring Dan Gilman from the Federal Trade Commission and Debra Richman from Harris Interactive, conference attendees had an enriching and educational experience.

May 8, 2014

The National Association of Chain Drug Stores and a national coalition working to achieve “provider status” for pharmacists under Medicare Part B have asked the Federal Trade Commission to back legislation to this effect, as well as other policies that would help pharmacists practice at the top of their education level, NACDS reported Thursday.

April 18, 2014

Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest.

April 11, 2014

Safeway on Thursday announced the receipt of a request for additional information and documents from the Federal Trade Commission in connection with the FTC's review of the Safeway/Albertson's merger.

March 19, 2014

The Electronic Retailing Self-Regulation Program on Tuesday announced it will refer direct response advertising for Dinamo to the Federal Trade Commission and the Food and Drug Administration after the marketer, Natures Flava, failed to respond to an ERSP inquiry.

March 14, 2014

The Federal Trade Commission is holding a public workshop in March to examine U.S. healthcare competition issues as healthcare spending swallows up a significant part of federal and state budgets. Among the topics up for discussion, according to reports, are retail clinics and telemedicine.

March 13, 2014

The American Association of Nurse Practitioners, a national professional membership organization for nurse practitioners of all specialties, is calling on state lawmakers to consider the consequences of undue restrictions on APRNs, or nurse practitioners, as recommended by the Federal Trade Commission.

March 10, 2014

Although the United States is still waiting for final practical guidelines from the Food and Drug Administration about the launch of biosimilars and the standards required to meet the threshold of interchangeability, the rest of the world seems to be barreling forward with the development and launch of these important medicines.

February 25, 2014

Bi-Lo Holdings and Delhaize Group on Tuesday announced they have received approval from the Federal Trade Commission to proceed with the transaction in which Bi-Lo Holdings will acquire substantially all of the stores in the Sweetbay, Harveys and Reid’s supermarket chains from Delhaize.

January 31, 2014

The National Advertising Division has referred to the Federal Trade Commission advertising claims made by Brain Research Labs, for Procera AVH, following the company’s failure to abide by the terms of an NAD decision.

January 20, 2014

Kroger and Harris Teeter Supermarkets on Friday announced that the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the pending merger transaction between the two companies.

January 15, 2014

The National Advertising Division referred advertising claims made by Coorga Nutraceuticals Corp. for its Grey Defense dietary supplements to the Federal Trade Commission.

January 7, 2014

The Federal Trade Commission announced a law enforcement initiative stopping national marketers that used deceptive advertising claims to peddle fad weight-loss products, from food additives and skin cream to dietary supplements.

December 12, 2013

The National Advertising Division referred advertising claims made by Bremmen Clinical, for its Vysera-CLS weight-loss supplement, to the Federal Trade Commission for further review.

November 27, 2013

NEW YORK — The National Advertising Division has referred advertising claims made by Maxam Nutraceuticals for its PCA dietary supplement to the Federal Trade Commission for further review, after the company declined to participate in a review of its claims.

The Council for Responsible Nutrition challenged claims made by Maxam in television and Internet advertising, including:

October 17, 2013

Prasco Labs will distribute an authorized generic for reducing serum phosphate in patients with end-stage renal disease under a contract with Shire, Prasco said Thursday.

August 9, 2013

Actavis and Warner Chilcott have received approval from all necessary antitrust clearances for their merger from regulators outside the United States, the companies said.

August 8, 2013

The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.

July 24, 2013

Mylan has settled with the makers of a drug used to treat cancer in a patent-infringement lawsuit, the generic drug maker said.

July 15, 2013

The National Advertising Division referred to the Federal Trade Commission advertising claims made by Fiore RX, for its Antifungal Nail Lacquer after the company failed to respond to an NAD inquiry.

July 11, 2013

Actavis and Warner Chilcott announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Warner Chilcott.

June 18, 2013

Half a loaf, the saying goes, is better than none. For the generic drug industry, that means that the Supreme Court handed it a partial victory Monday by ruling that “pay for delay” patent settlements between brand name and generic drug companies aren’t necessarily illegal and should be considered on a case-by-case, “rule of reason” approach by the Federal Trade Commission, which staunchly opposes the practice.